REM-422, a MYB mRNA Degrader, in Recurrent/Metastatic Adenoid Cystic Carcinoma (ACC)

• REM-422, orally available small molecule targeting MYB, is well-tolerated at RP2D (24mg)
• REM-422 shows anti-tumor activity in biomarker positive R/M ACC at RP2D
• REM-422 has indication expansion opportunities in additional solid tumors and hematological malignancies

Speakers:

Dominic Reynolds

Chief Scientific Officer

Remix Therapeutics